Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy

Research output: Contribution to journalArticle

7 Citations (Scopus)


A free radical scavenger Edaravone is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Of great importance for regenerative therapy and gene therapy are the neural stem cells which are intrinsically activated or exogenously transplanted. Addition of NTFs greatly enhanced an intrinsic migration or invasion of stem cells into the scaffold, which could provide a future regenerative potential against ischemic brain damage at chronic stage.

Original languageEnglish
Pages (from-to)896-898
Number of pages3
JournalClinical Neurology
Issue number11
Publication statusPublished - Nov 2008



  • Cerebral infarction
  • Edaravone
  • Gene therapy
  • Neuroprotection
  • Restorative therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this